Journals / Journal of Medicine and Palliative Care / 2022 / Cilt: 3 - Sayı: 3

Evaluation of Bethesda IV-V thyroid nodules: clinical experience

Bethesda IV-V tiroid nodüllerinin değerlendirilmesi: klinik deneyim

Pages
152–157
Publication Date
2022-09-26
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

While benign pathologies are considered in DC-IV diagnoses; If the diameter of DC-V cytologically diagnosed nodules is larger than 20 mm, OTC should be considered primarily, and if less than 20 mm, PTC should be considered.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: The malignancy rate in cases operated for thyroid nodule is approximately 5-10%, and although this rate shows significant differences according to Bethesda categories, there is a high risk of malignancy in categories IV and V compared to other categories.
📊
Key Findings & Data:Material and Method: A total of 780 patients who were diagnosed with thyroid nodules and underwent surgery at our center between 2011 and 2021 were included in the study.
💡
Conclusion & Impact:While benign pathologies are considered in DC-IV diagnoses; If the diameter of DC-V cytologically diagnosed nodules is larger than 20 mm, OTC should be considered primarily, and if less than 20 mm, PTC should be considered.
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Tiroid neoplazmaları · tiroid nodülü · ince iğne biyopsisi

Abstract

Introduction: The malignancy rate in cases operated for thyroid nodule is approximately 5-10%, and although this rate shows significant differences according to Bethesda categories, there is a high risk of malignancy in categories IV and V compared to other categories. In our study, we examined the clinicopathological factors affecting the success of cytological diagnosis in nodules diagnosed with Bethesda IV-V. Material and Method: A total of 780 patients who were diagnosed with thyroid nodules and underwent surgery at our center between 2011 and 2021 were included in the study. The preoperative cytological diagnoses of the patients were categorized using the Bethesda classification system. The demographic data of the patients, Bethesda classification of the nodules, and postoperative histopathological examination results were evaluated in subgroups, and their significance was determined. Results: The age group with the highest number of cases was 45-59 years, and the female/male ratio of the whole cohort was 3:1. The rate of palpable nodules was 41.8% for the malignant diagnosis group and 58.2% for the benign diagnosis group. In both malignant and benign groups, 20-mm nodules with a DC-V diagnosis and PTC in smaller nodules. While benign pathologies are considered in DC-IV diagnoses; If the diameter of DC-V cytologically diagnosed nodules is larger than 20 mm, OTC should be considered primarily, and if less than 20 mm, PTC should be considered.

Özet

Amaç: Tiroidde nodül nedeniyle opere edilen olgularda malignite oranı yaklaşık %5-10 olup, bu oran Bethesda kategorilerine göre önemli farklılıklar göstermekle birlikte diğer kategorilere göre kategori IV ve V’te yüksek malignite riski mevcuttur. Biz çalışmamızda Bethesda IV-V tanısı alan nodüllerde sitolojik tanı başarısını etkileyen klinikopatolojik etkenleri inceledik. Gereç ve Yöntem: Çalışmaya merkezimizde 2016-2021 yılları arasında tiroid nodülü tanısı alan ve opere edilen 780 hasta dahil edildi. Hastaların preoperatif sitolojik tanıları Bethesda Sistemi kullanılarak sınıflandırıldı. Hastaların demografik verileri, nodüllerin Bethesda sınıflandırması ve postoperatif histopatolojik inceleme sonuçları alt gruplar halinde değerlendirilerek anlamlı sonuçlar raporlandı. Bulgular: Olguların en yoğun olarak bulunduğu yaş grubu 45-59 olup, K/E oranın 3:1 olduğu görülmektedir. Malign tanı grubundaki nodüllerin %41,8’inin; benign tanı grubundakilerin %58,2’sinin palpabl olduğu görülmektedir. 20 mm

🔖

Cite This Article

CELEPLİ, S., BİGAT, İ., TÜRKOĞLU, B., TANRISEVEN, M., CELEPLİ, P., DONMEZ, L. (2022). Evaluation of Bethesda IV-V thyroid nodules: clinical experience. Journal of Medicine and Palliative Care, Cilt: 3 - Sayı: 3, 152–157. https://ajindex.com/articles/777625

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Murbeth S, Rousarova M, Scherb H, Lengfelder E. Thyroid cancer has increased in the adult populations of countries moderately affected by Chernobyl fallout. Med Sci Monit 2004; 10: CR300–CR306. Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016; 130: 150–60.
  2. Ha SM, Kim JK, Baek JH. Detection of malignancy among suspicious thyroid nodules Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1-133.
  3. Lupoli GA, Fonderico F, Colarusso S, et al. Current management of differentiated thyroid carcinoma. Med Sci Monit 2005; 11: RA368-373. Bombil I, Bentley A, Kruger D, Luvhengo TE. Incidental cancer in multinodular goiter post thyroidectomy. S Afr J Surg 2014; 52: 5-9.
  4. He Y, Liu S, Guo H, Shi B. Incidental finding of papillary thyroid carcinoma with BRAFV600E mutation in a patient with coexistent primary hyperparathyroidism and Graves’ hyperthyroidism. BMJ Case Rep 2014; 2014: bcr2013203436. Farrell E, Heffron C, Murphy M, O’Leary G, Sheahan P. Impact of lymphocytic thyroiditis on incidence of pathological incidental thyroid carcinoma. Head Neck 2017; 39: 122-7.
  5. Yazgan A, Balci S, Dincer N, et al. Hurthle cell presence alters the distribution and outcome of categories in the Bethesda system for reporting thyroid cytopathology. Cytopathology 2014; 25: 185-9.
  6. Aschebrook-Kilfoy B, Grogan RH, Ward MH, Kaplan E, Devesa, SS. Follicular thyroid cancer incidence patterns in the United States, 1980–2009. Thyroid 2013; 23: 1015–21.
  7. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid 2009; 19: 1159-65.
  8. Jung CK, Little MP, Lubin JH, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J. Clin. Endocrinol Metab 2014; 99; 276– 85. Grani G, Sponziello M, Pecce V, Ramundo V, Durante C. Contemporary thyroid nodule evaluation and management., J Clin Endocrinol Metab Review 2020; 105: 2869-83.
  9. Segovia IG, Gallowitsch HJ, Kresnik E et al. Descriptive epidemiology of thyroid carcinoma in Carinthia, Austria: 1984–2001. Histopathologic features and tumor classification of 734 cases under elevated gen